AMENDMENTS TO THE CLAIMS

Claim 1-7. (Cancelled)

Claim 8. (Previously presented) A veterinary pharmaceutical composition for controlling parasites in or on mammals comprising at least one compound of formula (I)



I,

in which

R_1 is hydrogen, C_1-C_6alkyl, halo-C_1-C_6alkyl, cyano-C_1-C_6alkyl, C_1-C_6alkoxymethyl or benzyl;

R_2, R_3, R_4, R_5 and R_6 are either, independently of one another, hydrogen, halogen, unsubstituted or mono- or polyhalogenated C_1-C_6alkyl, unsubstituted or mono- or polyhalogenated C_2-C_6alkenyl, unsubstituted or mono- or polyhalogenated C_2-C_6alkynyl; unsubstituted or mono- or polysubstituted C_1-C_6alkoxy, unsubstituted or mono- or polysubstituted halo-C_1-C_6alkoxy, unsubstituted or mono- or polysubstituted C_3-C_6cycloalkyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen and C_1-C_6alkyl; or unsubstituted or mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl, halo-C_1-C_6alkylsulfonyl, C_1-C_6alkylamino or di-C_1-C_6alkylamino;

or R_2 and R_3 are together C_2-C_6alkylene;

either

R_7 is unsubstituted or mono- or polysubstituted C_3-C_6cycloalkoxy, unsubstituted or mono- or polysubstituted C_3-C_6cycloalkylthio, unsubstituted or mono- or polysubstituted (C_3-C_6cycloalkyl)(R_9)N, in which the substituents in each case are chosen from the group consisting of halogen and C_1-C_6alkyl; hetaryl or hetaryloxy;

and

R_8 is halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_2-C_6alkenyl, halo-C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_2-C_6alkenyloxy, halo-C_2-C_6-alkenyloxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfonyloxy, halo-C_1-C_6alkyl-sulfonyloxy, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl, halo-C_1-C_6alkyl-sulfonyl, C_2-C_6alkenylthio, halo-C_2-C_6alkenylthio, C_2-C_6alkenylsulfinyl, halo-C_2-C_6alkenylsulfinyl,

C_2-C_6alkenylsulfonyl, halo-C_2-C_6alkenylsulfonyl, C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_1-C_6alkylsulfonylamino, halo-C_1-C_6alkylsulfonylamino, C_1-C_6alkylcarbonyl, halo-C_1-C_6alkylcarbonyl, C_1-C_6alkoxycarbonyl, C_1-C_6alkylaminocarbonyl, di-C_1-C_6alkylaminocarbonyl, unsubstituted or mono- or polysubstituted phenylamino, unsubstituted or mono- or polysubstituted phenylcarbonyl; unsubstituted or mono- or polysubstituted phenylmethoxyimino; unsubstituted or mono- or polysubstituted phenylhydroxymethyl; unsubstituted or mono- or polysubstituted 1-phenyl-1-hydroxyethyl; unsubstituted or mono- or polysubstituted phenylchloromethyl; unsubstituted or mono- or polysubstituted phenylcyanomethyl; unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl and halo-C_1-C_6alkylsulfonyl; unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl and halo-C_1-C_6alkylsulfonyl; unsubstituted or mono- or polysubstituted phenylacetylenyl, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl and halo-C_1-C_6alkylsulfonyl; or unsubstituted or mono- or polysubstituted pyridyloxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, halo-C_1-C_6alkoxy, C_1-C_6alkylthio, halo-C_1-C_6alkylthio, C_1-C_6alkylsulfinyl, halo-C_1-C_6alkylsulfinyl, C_1-C_6alkylsulfonyl and halo-C_1-C_6alkylsulfonyl;

or R_7 and R_8 are together C_3-C_5alkylene;

Ar is unsubstituted or mono- or polysubstituted phenyl, unsubstituted or mono- or polysubstituted hetaryl, unsubstituted or mono- or polysubstituted naphthyl or unsubstituted or mono- or polysubstituted quinolyl, in which in each case the substituents can be independent of one another and are chosen from the group consisting of R_7 and R_8;

R_9 is hydrogen, C_1-C_6alkyl, halo-C_1-C_6alkyl, allyl, C_1-C_6alkoxymethyl or -C(O)R_{10};

R_{10} is C_1-C_6alkyl, halo-C_1-C_6alkyl or C_1-C_6alkoxymethyl;

W is O, S, S(O_2) or N(R_{11});

R_{11} is hydrogen or C_1-C_6alkyl;

a is 1, 2, 3 or 4;

b is 0, 1, 2, 3 or 4; and

n is 0, 1 or 2,

in which, if R_7 is hetaryloxy, the hetaryl group in R_7 is other than pyridyl; and

veterinary acceptable carriers and/or dispersants; whereby said veterinary pharmaceutical composition kill said parasites that live on or in said mammal when applied to said mammal.

Claims 9 -18. (Cancelled)

Claim 19. (Currently amended) A method of treating a mammal for parasites that live on or in said mammal comprising administering to said mammal in need of treatment thereof a parasiticidal effective amount of the veterinary pharmaceutical composition of Claim 8 wherein said veterinary pharmaceutical composition is well-tolerated by said mammal.

Claim 20. (Previously presented) The method of Claim 19 wherein said administration to said animal is topically, perorally, parenterally, or subcutaneously.

Claim 21. (Previously presented) The method of Claim 19 wherein said veterinary pharmaceutical composition of Claim 8 is in a formulation consisting of the group of pour-on, spot-on, tablet, chewie, powder, boli, capsules, suspension, emulsion, solution, injectable, water-additive, and food-additive.

Claim 22. (Previously presented) The method of Claim 19 wherein said parasites are endo-parasites.

Claim 23. (Previously presented) The method of Claim 19 wherein said parasites are helminthes.

Claim 24. (Previously presented) The method of Claim 22 wherein said endo-parasites are nematodes and trematodes.

Claim 25. (Currently amended) A method of controlling parasites that live on or in a mammal comprising administering to said mammal the veterinary pharmaceutical composition of Claim 8 wherein said veterinary pharmaceutical composition is well-tolerated by said mammal.

Claim 26. (Previously presented) The method of Claim 25 whereby said veterinary pharmaceutical composition is administered to said mammal topically, perorally, parenterally, or subcutaneously.

Claim 27. (Previously presented) The method of Claim 25 whereby said veterinary pharmaceutical composition is in a formulation consisting of the group of pour-on, spot-on,

tablet, chewie, powder, boli, capsules, suspension, emulsion, solution, injectable, water-additive, and food-additive.

Claim 28. (Previously presented) The method of Claim 25 wherein said parasites are endo-parasites.

Claim 29. (Previously presented) The method of Claim 28 wherein said endo-parasites are helminthes.

Claim 30. (Previously presented) The method of Claim 28 wherein said endo-parasites are nematodes and trematodes.

Claim 31. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which

R_7 is unsubstituted or mono- or polysubstituted C_3-C_6cycloalkoxy, unsubstituted or mono- or polysubstituted C_3-C_6cycloalkylthio or unsubstituted or mono- or polysubstituted (C_3-C_6cycloalkyl)(R_9)N, in which the substituents in each case are chosen from the group consisting of halogen and C_1-C_6alkyl.

Claim 32. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which

R_1 is hydrogen, C_1-C_4alkyl or halo-C_1-C_4alkyl;

R_2, R_3, R_4, R_5 and R_6 are, independently of one another, hydrogen, unsubstituted or mono- or polyhalogenated C_1-C_6alkyl, unsubstituted or mono- or polyhalogenated C_2-C_6alkenyl or unsubstituted or mono- or polyhalogenated C_2-C_6alkynyl;

R_7 is unsubstituted C_3-C_6cycloalkoxy, unsubstituted C_3-C_6cycloalkylthio or unsubstituted (C_3-C_6cycloalkyl)(R_9)N;

R_8 is halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_2-C_4alkenyl, halo-C_2-C_4alkenyl, C_2-C_4alkynyl, C_3-C_5cycloalkyl, C_2-C_4alkenyloxy, halo-C_2-C_4alkenyloxy, C_1-C_4alkylthio, halo-C_1-C_4alkylthio, C_2-C_4alkenylthio, halo-C_2-C_4alkenyl-thio, C_1-C_4alkylamino, di-C_1-C_4alkylamino, C_1-C_4alkylcarbonyl, halo-C_1-C_4alkylcarbonyl, C_1-C_4alkoxycarbonyl, unsubstituted or mono- or polysubstituted phenylamino, unsubstituted or mono- or polysubstituted phenylcarbonyl; unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_1-C_4alkylthio and halo-C_1-C_4alkylthio; unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_1-C_4alkylthio and halo-C_1-C_4alkylthio; or unsubstituted or mono- or polysubstituted pyridyloxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_1-C_4alkylthio and halo-C_1-C_4alkylthio;

Ar is unsubstituted or mono- or polysubstituted phenyl or unsubstituted or mono- or polysubstituted hetaryl, in which in each case the substituents can be independent of one another and are chosen from the group consisting of R_7 and R_8;

R_9 is hydrogen, C_1-C_6alkyl or halo-C_1-C_6alkyl;

W is O, S or N(R_{11});

R_{11} is hydrogen or C_1-C_4alkyl;
a is 1, 2 or 3;

b is 0, 1, 2 or 3; and
n is 0, 1 or 2.

Claim 33. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which
R_1 is hydrogen or C_1-C_4alkyl;
R_2, R_3, R_4, R_5 and R_6 are, independently of one another, hydrogen or unsubstituted or mono- or polyhalogenated C_1-C_6alkyl;

R_7 is unsubstituted C_3-C_5cycloalkoxy or unsubstituted (C_3-C_5cycloalkyl)(R_9)N;
R_8 is halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_3-C_5cycloalkyl, C_1-C_4alkylcarbonyl, C_1-C_4alkoxycarbonyl, unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy and halo-C_1-C_4alkoxy; or unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C_1-C_4alkyl, halo-C_1-C_4alkyl, C_1-C_4alkoxy, halo-C_1-C_4alkoxy, C_1-C_4alkylthio and halo-C_1-C_4alkylthio;

Ar is unsubstituted or mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from R_7 and R_8;

R_9 is hydrogen or C_1-C_4alkyl;
W is O or S;
a is 1 or 2;

b is 0 or 1; and
n is 1 or 2.

Claim 34. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which
R_1 is hydrogen;

R_2, R_3, R_4, R_5 and R_6 are, independently of one another, hydrogen or unsubstituted C_1-C_4alkyl;

R_7 is unsubstituted C_3-C_4cycloalkoxy or unsubstituted (C_3-C_4cycloalkyl)(R_9)N;

R_8 is halogen, nitro, cyano, C_1-C_2alkyl, halo-C_1-C_2alkyl, C_1-C_2alkoxy, halo-C_1-C_2alkoxy, C_3-C_4cycloalkyl, C_1-C_2alkylcarbonyl or C_1-C_2alkoxycarbonyl;

Ar is mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from R_8;

R_9 is hydrogen or C_1-C_2alkyl;
W is O;

R_{11} is methyl;
a is 1;

b is 0; and

n is 2.

Claim 35. (Previously presented) The veterinary pharmaceutical composition of Claim 8, in which the at least one compound of formula (I) has the name N-[2-[2-cyano-1-[2-(cyclopropylmethylamino)-4,5-difluorophenoxy]propyl]-4-trifluoromethoxybenzamide.